Product News and Recalls

New pharmaceuticals boost profits for Bayer

German corporation Bayer will rely on commercialization of its new pharmaceutical products to bolster its profits in the year ahead.

A recent report by the corporate giant trumpets its sales in the past year, stating they rose by 4.1 percent in 2011 to $48.2 million. The report specifically mentions Bayer’s HeathCare subgroup, responsible for pharmaceutical products, as contributing to the profitability.

“One of our strengths continues to be our well-stocked development pipeline in pharmaceuticals,” Bayer CEO Dr. Marijn Dekkers said. Several times, the report mentions that Bayer sees getting new pharmaceutical products on the market as key to making even higher profits in the year ahead.

A number of lawsuits involving multiple plaintiffs allege that Bayer’s haste in getting pharmaceutical products on the market without adequate warnings has killed and injured users of its birth control pills Yasmin, Yaz, Beyaz, and Ocella.

Those pills – as well as Beyaz, Gianvi, Loryna, Safyral, Syeda and Zarah — contain a compound created by Bayer called drospirenone, which is a synthetic progestogen that may elevate the levels of potassium in the body.

On May 31, 2011, the FDA issued its fourth warning about birth control pills containing drospirenone, citing two recent studies that found an increased risk of blood clots compared to the risk associated with the use of birth control pills containing levonorgestrel.

If you’ve developed a blood clot while taking any of those pills, you may be eligible to recover damages. For more information, contact Lopez McHugh for a free consultation with an attorney who can answer your questions and ensure your legal rights are protected.